Chugai and Biofourmis Enter into New Partnership
Thursday, March 02, 2023
Chugai Pharmaceutical and Biofourmis, announced that they have entered into a new partnership agreement for the continued development and real-world use of digital solutions to objectively measure pain in patients with endometriosis. Endometriosis affects approximately 10%1 of all women of reproductive age and 70% of women with chronic pelvic pain, resulting in a reduced quality of life.
This partnership agreement aims to develop new digital solutions for the objective assessment and management of pain associated with endometriosis, which have been jointly developing since July 2020.
The collaboration will focus on:
• Continued development of objective measurement technology for pain associated with endometriosis
• Advancing progress on a technology platform for a real-world data driven pain measurement and supporting patient care
• Virtual speciality care delivery by Biofourmis for endometriosis patients in the U.S.
• Utilisation of data collected during research and development and post-marketing of Chugai’s investigational product for the treatment of endometriosis pain, AMY109.
Expanding this collaboration from research and development to real-world use demonstrates the scalability and flexibility of Biofourmis’ end-to-end platform and solutions for both drug development and healthcare delivery.
